---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002438"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:02:27.110446+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intellia Therapeutics provides strategic update, cash ~$1.0B, workforce reduction of ~15%

## Summary
- Cash, cash equivalents and marketable securities ~$1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
- Workforce reduction of approximately 15% and pause of select exploratory research-stage programs to focus on key priorities.
- Initiated pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for ATTR amyloidosis with cardiomyopathy; first patient dosing expected Q1 2024.
- Completed enrollment and dosing in Phase 2 portion of NTLA-2002 study for hereditary angioedema; Phase 3 initiation planned 2H 2024.
- Board member John Crowley departed in December following his appointment as CEO of BIO.

## SEC filing metadata
- accession: 0001193125-24-002438
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312524002438/0001193125-24-002438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312524002438/d655921d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002438
- JSON: https://secwatch.observer/filing/0001193125-24-002438.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002438.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: preliminary results
  source text: Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2023, Intellia Therapeutics, Inc. (the “Company”) announced on January 4, 2024, that it expects to report that it had approximately $1.0 billion of cash, cash equivalents and marketable securities as of December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312524002438/0001193125-24-002438-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.